Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas
NCT00006436Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2001
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin in diffuse large B-cell lymphoma (DLBCL), sponsored by National Cancer Institute. Started Jan 2001; status: completed.
02
Drugs
etoposideprednisonevincristinecyclophosphamidedoxorubicin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00006436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006436.